Cargando…
Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
Antibody–drug conjugate (ADC) is a milestone in targeted cancer therapy that comprises of monoclonal antibodies chemically linked to cytotoxic drugs. Internalization of ADC takes place via clathrin-mediated endocytosis, caveolae-mediated endocytosis, and pinocytosis. Conjugation strategies, endocyto...
Autores principales: | Kalim, Muhammad, Chen, Jie, Wang, Shenghao, Lin, Caiyao, Ullah, Saif, Liang, Keying, Ding, Qian, Chen, Shuqing, Zhan, Jinbiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546728/ https://www.ncbi.nlm.nih.gov/pubmed/28814834 http://dx.doi.org/10.2147/DDDT.S135571 |
Ejemplares similares
-
Engineered scPDL1-DM1 drug conjugate with improved in
vitro analysis to target PD-L1 positive cancer cells and
intracellular trafficking studies in cancer therapy
por: Kalim, Muhammad, et al.
Publicado: (2020) -
Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells
por: Liang, Keying, et al.
Publicado: (2021) -
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
por: Ritchie, Michael, et al.
Publicado: (2013) -
Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody
por: Kalim, Muhammad, et al.
Publicado: (2022) -
TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation
por: Shen, Ying, et al.
Publicado: (2020)